Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Dr. Steven Quay, Chairman and Chief Executive Officer to participate in Fireside Chat with
Emily Bodnar, HCW Biotech Research Analyst

SEATTLE, Aug. 28, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, today announced that Dr. Steven Quay, Chairman and Chief Executive Officer, will participate in a fireside chat with biotech research analyst, Emily Bodnar, at the H.C. Wainwright (HCW) 27th Annual Global Investment Conference on Monday, September 8, 2025, at 3:00 p.m. ET, at the Lotte New York Palace Hotel in New York City.

Read more at prnewswire.com